| Literature DB >> 26167508 |
Huifen Xu1, Cuilan Zhou2, Andy K Zhang1, Wen Li1, Jia Zhang1, Kai Li1.
Abstract
Not all proteins are tolerable to mutations. Whether a specific protein can be a mutable target is of importance in the biotechnology and pharmaceutical industry. This study reported a novel mutagenesis assay using tandem NNT and NNC oligonucleotides to test the mutability of a candidate gene. These two tandem oligonucleotides avoid the risk of forming nonsense mutations and render flexibility of truncating or expanding the insertion size. As a reporter gene, ZeoR (zeocin resistance gene) was confirmed to have a high tolerance for mutagenesis by this new assay.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26167508 PMCID: PMC4488517 DOI: 10.1155/2015/950873
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Plasmid maps of pZAmpA and pZAmpB. (a) The inserted BaeI site and its nucleotide sequences are marked and illustrated. (b) The detailed subcloning sites and their specific sequences before and after cloning are marked.
Designed mutants keep the zeocin resistance gene in frame.
| Size (nt) | Targeted gene | Sequence | A : T : C : G ratio |
|---|---|---|---|
| 32 | n.a | CTAGAGATATCGTCGACCTGCAGAAGCTTCCG | 8 : 7 : 9 : 8 |
| 33 | n.a | CCTAGAGATATCGTCGACCTGCAGAAGCTTCCG | 8 : 7 : 10 : 8 |
| 111 | n.a | CCTAGAGATATCGCATGCCTGCAGGTCGACTCTAGAGGATCCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTACAACGTCGTGTCTGGGAAAACCCAAGCTTCCG | 24 : 25 : 33 : 29 |
| 112 | n.a | CCTAGAGATATCGCATGCCTGCAGGTCGACTCTAGAGGATCCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTACAACGTCGTGTCTGGGAAAACCCCAAGCTTCCG | 24 : 25 : 34 : 29 |
| 51 | CCR5-1-3N | TGCATCAACCCCATCATCTATAGATCTGTCGGGGAGAAGTTCAGAAACTAT | 16 : 13 : 12 : 10 |
| 52 | CCR5-1-3N+1 | TGCATCAACCCCATCATCTATAGATCTGTCGGGGAGAAGTTCAGAAACTATC | 16 : 13 : 13 : 10 |
| 39 | EGFR 15-1-3N | AAGCTGGCTTTCGGAGATGTTTTGATAGCGACGGAATTC | 9 : 12 : 6 : 12 |
| 40 | EGFR 15-1-3N+1 | AAGCTGGCTTTCGGAGATGTTTTGATAGCGACGGCAATTC | 9 : 12 : 7 : 12 |
| 42 | EGFR 18-1-3N | AAGCTGTCGCTATCAAGGAATCGAAAGCCAACAAGGCAATTC | 16 : 7 : 10 : 9 |
| 43 | EGFR 18-1-3N+1 | AAGCTGTCGCTATCAAGGAATCGAAAGCCAACAAGGCAAATTC | 17 : 7 : 10 : 9 |
Figure 2Chromographic illustration showing the correct sequences of the pZAmpA and pZAmpB plasmids.
Figure 3Chromographic illustration showing the correct sequences of inserts.
Nucleotides used at the degenerate sites corresponding to the tandem NNT and NNC oligonucleotides in the mutants sequenced.
| NNT | Sequence | NNC | Sequence |
|---|---|---|---|
| 1 | CTTGATGGT | 1 | GACAACAACGAC |
| 2 | CATTTTACTAGT | 2 | ACCAACAACATCCAC |
| 3 | AATTATAATGCTAATGGTCTT | 3 | CTCAGCTTCCTCCCCTGC |
| 4 | AGTACTGATTATGTTAATCAT | 4 | AACATCTTCAGCGGCGACCGC |
| 5 | TCTGATTCTCCTTCTCTTCAT | ||
| 6 | ACTACTCCTTGTTCTGTTCTT | 5 | AGCTCCGACGACGGCTTCCCCTTC |
| 7 | TCTGTTACTGATCTTCCTATT | 6 | ATCAACATCCACTGCTTCGGCCAC |
| 8 | AGTGATCGTGCTTTTGTTAGT | 7 | AGCTCCGACGACGGCTTCCCCTTC |
| 9 | CCTGCTCGTCGTCGTCATCGT | 8 | CACACCCTCCGCCCCGGCACCTCC |
| 10 | GCTTATTCTCTTGTTGTTCGTCGT | 9 | CACTGCAGCCTCTCCAACTACTGC |
| 11 | GGTGATGTTCGTAGTAATCATGGT | 10 | AACCACGACACCAACCGCAACTTC |
| 12 | GTTGGTTCTCGTCGTATTTGTGTT | 11 | AGCTCCCCCCCCAACTTCACCGAC |
| 13 | TCTCATGTTCCTGCTACTTGTCGTCTT | 12 | AACCTCCACGACCTCGGCCACTAC |
| 14 | ATTGGTGGTGCTCTTCCTACTCATTGT | 13 | AACCACCACTCCACCTTCTGCCAC |
| 15 | CTTCATCGTCCTCCTCTTCCTGTTATT | ||
| 16 | ATTATTTTTACTGCTTGTCCTTGTATT | ||
| 17 | TCTCCTCTTAATGTTGGTGGTCGTCCTCGTGTTCGT | 14 | ATCCACCCCTCCCACTGCGTCGCCCTCTCC |
Amino acids deduced from nucleotides used at the degenerate sites corresponding to the tandem NNT and NNC oligonucleotides in the mutants sequenced.
| NNT | Sequence | NNC | Sequence |
|---|---|---|---|
| 1 | LDG | 1 | DNND |
| 2 | HFTS | 2 | TNNIH |
| 3 | NYNANGL | 3 | LSFLPC |
| 4 | STDYVNH | 4 | NIFSGDR |
| 5 | SDSPSLH | ||
| 6 | TTPCSVL | 5 | SSDDGFPF |
| 7 | SVTDLPI | 6 | INIHCFGH |
| 8 | SDRAFVS | 7 | SSDDGFPF |
| 9 | PARRRHR | 8 | HTLRPGTS |
| 10 | AYSLVVRR | 9 | HCSLSNYC |
| 11 | GDVRSNHG | 10 | NHDTNRNF |
| 12 | VGSRRICV | 11 | SSPPNFTD |
| 13 | SHVPATCRL | 12 | NLHDLGHY |
| 14 | IGGALPTHC | 13 | NHHSTFCH |
| 15 | LHRPPLPVI | ||
| 16 | IIFTACPCI | ||
| 17 | SPLNVGGRPRVR | 14 | IHPSHCVALS |
Advantage and disadvantage of completely and partially degenerated oligonucleotides in mutagenesis.
| Oligo type | Advantage | Disadvantage |
|---|---|---|
| NNN | Efficient for saturation mutagenesis | 5% chance of creating nonsense mutations |
|
| ||
| NNT | Tandem triplet can be used to test mutability of a target gene; both the bias of nucleotide use and the length of inserts can be tested | One triplet can be used for saturation mutagenesis when combined with NNG |
|
| ||
| NNC | Tandem triplet can be used to test mutability of a target gene, but the power may be lower than that of NNT; both the bias of nucleotide use and the length of inserts can be tested | One triplet can be used for saturation mutagenesis when combined with NNG |